Combination Treatment of PDS0101 and Pembrolizumab
PDS0101-HNC-301
Phase 3 other active
Quick answer
Combination Treatment of PDS0101 and Pembrolizumab for Recurrent Head and Neck Cancer is a Phase 3 program (other) at PDS Biotechnology Corp with 1 ClinicalTrials.gov record(s).
Program details
- Company
- PDS Biotechnology Corp
- Indication
- Recurrent Head and Neck Cancer
- Phase
- Phase 3
- Modality
- other
- Status
- active